Intra-Cellular Therapies
ITCI
$67.24
Share price
2.42%
Change (1 day)
12.95%
Change (1 year)
Categories
P/S ratio for Intra-Cellular Therapies (ITCI)
P/S ratio as of June 2024 (TTM): 13.7
According to Intra-Cellular Therapies's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 13.7129. At the end of 2023 the company had a P/S ratio of 14.9.
P/S ratio history for Intra-Cellular Therapies from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 14.9 | -25.87% |
| 2022 | 20.1 | -61.45% |
| 2021 | 52.2 | -54.05% |
| 2020 | 114 | -99.64% |
| 2019 | > 1000 | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | -100% |
| 2015 | > 1000 | 7862.53% |
| 2014 | 951 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | 9.08 | -33.76% | 🇺🇸 USA |
 MediciNova MNOV | 65.7 | 379.27% | 🇺🇸 USA |
 Curis CRIS | 6.39 | -53.43% | 🇺🇸 USA |